Join

Compare · ABT vs RPRX

ABT vs RPRX

Side-by-side comparison of Abbott Laboratories (ABT) and Royalty Pharma plc (RPRX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ABT and RPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • ABT is the larger of the two at $158.63B, about 4.9x RPRX ($32.17B).
  • Over the past year, ABT is down 31.7% and RPRX is up 67.4% - RPRX leads by 99.1 points.
  • Both names hit the wire about 5 times in the past 4 weeks.
  • ABT has more recent analyst coverage (25 ratings vs 12 for RPRX).
PerformanceABT-31.73%RPRX+67.39%
2025-06-09+0.00%2026-06-05
MetricABTRPRX
Company
Abbott Laboratories
Royalty Pharma plc
Price
-
-
Market cap
$158.63B
$32.17B
1M return
+5.60%
+10.25%
1Y return
-31.73%
+67.39%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
5
5
Recent ratings
25
12
ABT

Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.

RPRX

Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Latest ABT

Latest RPRX